Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 2
2020 6
2021 3
2022 4
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival.
Weber JS, Poretta T, Stwalley BD, Sakkal LA, Du EX, Wang T, Chen Y, Wang Y, Betts KA, Shoushtari AN. Weber JS, et al. Among authors: poretta t. Cancer Immunol Immunother. 2023 Apr;72(4):945-954. doi: 10.1007/s00262-022-03302-5. Epub 2022 Oct 5. Cancer Immunol Immunother. 2023. PMID: 36197494 Free PMC article. Clinical Trial.
Randomized study of remote telehealth genetic services versus usual care in oncology practices without genetic counselors.
Cacioppo CN, Egleston BL, Fetzer D, Burke Sands C, Raza SA, Reddy Malleda N, McCarty Wood E, Rittenburg I, Childs J, Cho D, Hosford M, Khair T, Khatri J, Komarnicky L, Poretta T, Rahman F, Shah S, Patrick-Miller LJ, Domchek SM, Bradbury AR. Cacioppo CN, et al. Among authors: poretta t. Cancer Med. 2021 Jul;10(13):4532-4541. doi: 10.1002/cam4.3968. Epub 2021 Jun 8. Cancer Med. 2021. PMID: 34102012 Free PMC article. Clinical Trial.
Correction to: Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival.
Weber JS, Poretta T, Stwalley BD, Sakkal LA, Du EX, Wang T, Chen Y, Wang Y, Betts KA, Shoushtari AN. Weber JS, et al. Among authors: poretta t. Cancer Immunol Immunother. 2023 Apr;72(4):955. doi: 10.1007/s00262-022-03351-w. Cancer Immunol Immunother. 2023. PMID: 36538061 Free PMC article. No abstract available.
19 results